Vitrectomy with or without preoperative intravitreal bevacizumab for proliferative diabetic retinopathy: A meta-analysis of randomized controlled trials

American Journal of Ophthalmology

Volumn 156, Issue 1, 2013, Pages

  Zhang, Zhi Hua ^a   Liu, Hai Yun ^a   Hernandez Da Mota, Sergio E ^b   Romano, Mario R ^c   Falavarjani, Khalil G ^d   Ahmadieh, Hamid ^e   Xu, Xun ^a   Liu, Kun ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b Clinica David Unidad Oftalmologica   (Mexico)

^c HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^d IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB;

ARTICLE; DIABETIC RETINOPATHY; DIATHERMY; DRUG SAFETY; HUMAN; META ANALYSIS; OPERATION DURATION; POSTOPERATIVE COMPLICATION; PREOPERATIVE CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINA HEMORRHAGE; RETINA TEAR; SYSTEMATIC REVIEW; TREATMENT OUTCOME; VITRECTOMY;

EID: 84879241921     PISSN: 00029394     EISSN: 18791891     Source Type: Journal    
DOI: 10.1016/j.ajo.2013.02.008     Document Type: Article

References (31)

1. S.E. Moss, R. Klein, and B.E. Klein The 14-year incidence of visual loss in diabetic population Ophthalmology 105 6 1998 998 1003
2. D.S. Fong, F.L. Ferris 3rd, M.D. Davis, and E.Y. Chew Causes of severe visual loss in the early treatment diabetic retinopathy study: ETDRS report no. 24. Early Treatment Diabetic Retinopathy Study Research Group Am J Ophthalmol 127 2 1999 137 141
3. R.T. Oyakawa, A.P. Schachat, R.G. Michels, and T.A. Rice Complications of vitreous surgery for diabetic retinopathy. I. Intraoperative complications Ophthalmology 90 5 1983 517 521
4. E. Iwata, S. Ueno, and K. Ishikawa Focal macular electroretinograms after intravitreal injections of bevacizumab for age-related macular degeneration Invest Ophthalmol Vis Sci 53 7 2012 4185 4190
5. G.M. El-Mollayess, Z. Mahfoud, A.R. Schakal, H.I. Salti, D. Jaafar, and Z.F. Bashshur Fixed-interval versus OCT-guided variable dosing of intravitreal bevacizumab in the management of neovascular age-related macular degeneration: a 12-month randomized prospective study Am J Ophthalmol 153 3 2012 481 489
6. P. Iacono, M.B. Parodi, and A. Papayannis Intravitreal ranibizumab versus bevacizumab for treatment of myopic choroidal neovascularization Retina 32 8 2012 1539 1546
7. M. Gharbiya, F. Cruciani, F. Parisi, G. Cuozzo, S. Altimari, and S. Abdolrahimzadeh Long-term results of intravitreal bevacizumab for choroidal neovascularisation in pathological myopia Br J Ophthalmol 96 8 2012 1068 1072
8. Mahdy RA, Nada WM, Fawzy KM, Alnashar HY, Almosalamy SM. Efficacy of intravitreal bevacizumab with panretinal photocoagulation followed by Ahmed valve implantation in neovascular glaucoma. J Glaucoma. http://dx.doi.org/10. 1097/IJG.0b013e318259aec4. 2012.07.11.
9. R.J. Campbell, S.S. Gill, S.E. Bronskill, J.M. Paterson, M. Whitehead, and C.M. Bell Adverse events with intravitreal injection of vascular endothelial growth factor inhibitors: nested case-control study BMJ 345 2012 e4203
10. E. Chen, and C.H. Park Use of intravitreal bevacizumab as a preoperative adjunct for tractional retinal detachment repair in severe proliferative diabetic retinopathy Retina 26 6 2006 699 700
11. H.A. El-Sabagh, W. Abdelghaffar, and A.M. Labib Preoperative intravitreal bevacizumab use as an adjuvant to diabetic vitrectomy: histopathologic findings and clinical implications Ophthalmology 118 4 2011 636 641
12. L.Q. Zhao, H. Zhu, P.Q. Zhao, and Y.Q. Hu A systematic review and meta-analysis of clinical outcomes of vitrectomy with or without intravitreal bevacizumab pretreatment for severe diabetic retinopathy Br J Ophthalmol 95 9 2011 1216 1222
13. M.S. Farahvash, A.R. Majidi, R. Roohipoor, and F. Ghassemi Preoperative injection of intravitreal bevacizumab in dense diabetic vitreous hemorrhage Retina 31 7 2011 1254 1260
14. J. Ahn, S.J. Woo, H. Chung, and K.H. Park The effect of adjunctive intravitreal bevacizumab for preventing postvitrectomy hemorrhage in proliferative diabetic retinopathy Ophthalmology 118 11 2011 2218 2226
15. S.E. Hernández-Da Mota, and S.M. Nuñez-Solorio Experience with intravitreal bevacizumab as a preoperative adjunct in 23-G vitrectomy for advanced proliferative diabetic retinopathy Eur J Ophthalmol 20 6 2010 1047 1052
16. A.R. Jadad, R.A. Moore, and D. Carroll Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17 1 1996 1 12
17. M. Egger, G. Davey Smith, M. Schneider, and C. Minder Bias in meta-analysis detected by a simple, graphical test BMJ 315 7109 1997 629 634
18. S. Rizzo, F. Genovesi-Ebert, E. Di Bartolo, A. Vento, S. Miniaci, and G. Williams Injection of intravitreal bevacizumab (Avastin) as a preoperative adjunct before vitrectomy surgery in the treatment of severe proliferative diabetic retinopathy (PDR) Graefes Arch Clin Exp Ophthalmol 246 6 2008 837 842
19. R. di Lauro, P. De Ruggiero, R. di Lauro, M.T. di Lauro, and M.R. Romano Intravitreal bevacizumab for surgical treatment of severe proliferative diabetic retinopathy Graefes Arch Clin Exp Ophthalmol 248 6 2010 7857 7891
20. M. Modarres, H. Nazari, K.G. Falavarjani, M. Naseripour, M. Hashemi, and M.M. Parvaresh Intravitreal injection of bevacizumab before vitrectomy for proliferative diabetic retinopathy Eur J Ophthalmol 19 5 2009 848 852
21. H. Ahmadieh, N. Shoeibi, M. Entezari, and R. Monshizadeh Intravitreal bevacizumab for prevention of early postvitrectomy hemorrhage in diabetic patients: a randomized clinical trial Ophthalmology 116 10 2009 1943 1948
22. A.M. El-Batarny Intravitreal bevacizumab as an adjunctive therapy before diabetic vitrectomy Clin Ophthalmol 2 4 2008 709 716
23. D. da R Lucena, J.A. Ribeiro, and R.A. Costa Intraoperative bleeding during vitrectomy for diabetic tractional retinal detachment with versus without preoperative intravitreal bevacizumab (IBeTra study) Br J Ophthalmol 93 5 2009 688 691
24. M.A. Abdelhakim, T.A. Macky, K.A. Mansour, and H.A. Mortada Bevacizumab (Avastin) as an adjunct to vitrectomy in the management of severe proliferative diabetic retinopathy: a prospective case series Ophthalmic Res 45 1 2011 23 30
25. T. Hattori, H. Shimada, H. Nakashizuka, Y. Mizutani, R. Mori, and M. Yuzawa Dose of intravitreal bevacizumab (Avastin) used as preoperative adjunct therapy for proliferative diabetic retinopathy Retina 30 5 2010 761 764
26. Y. Ma, Y. Zhang, T. Zhao, and Y.R. Jiang Vascular endothelial growth factor in plasma and vitreous fluid of patients with proliferative diabetic retinopathy patients after intravitreal injection of bevacizumab Am J Ophthalmol 153 2 2012 307 313
27. L.P. Aiello, R.L. Avery, and P.G. Arrigg Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders N Engl J Med 331 22 1994 1480 1487
28. C.M. Yang, P.T. Yeh, C.H. Yang, and M.S. Chen Bevacizumab pretreatment and long-acting gas infusion on vitreous clear-up after diabetic vitrectomy Am J Ophthalmol 146 2 2008 211 217
29. Q. Zhu, F. Ziemssen, and S. Henke-Fahle Vitreous levels of bevacizumab and vascular endothelial growth factor-A in patients with choroidal neovascularization Ophthalmology 115 10 2008 1750 1755
30. R.J. Van Geest, S.Y. Lesnik-Oberstein, and H.S. Tan A shift in the balance of vascular endothelial growth factor and connective tissue growth factor by bevacizumab causes the angiofibrotic switch in proliferative diabetic retinopathy Br J Ophthalmol 96 4 2012 587 590
31. J.F. Arevalo, M. Maia, and H.W. Flynn Jr. Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy Br J Ophthalmol 92 2 2008 213 216